1. CAR T-Cell Therapy for Relapsed/Refractory Aggressive Large B-Cell Lymphoma.
- Author
-
Gideon, Jacklyn
- Subjects
- *
PATIENT aftercare , *OCCUPATIONAL roles , *NEUROTOXICOLOGY , *SYNDROMES , *CELLULAR therapy , *CELL receptors , *B cell lymphoma , *CANCER relapse , *TREATMENT effectiveness , *CONTINUUM of care , *CYTOKINE release syndrome , *MEDICAL referrals , *HEALTH care teams , *COMMUNICATION , *NURSES , *INDEPENDENT living , *T cells , *NURSE practitioners , *REHABILITATION , *IMMUNOTHERAPY , *ANTIGENS , *SYMPTOMS , *MIDDLE age - Abstract
Cellular immunotherapy with CD19-directed chimeric antigen receptor (CAR) T-cell therapy has changed the treatment landscape for aggressive B-cell non-Hodgkin lymphoma (B-NHL). Three CAR T-cell therapies are commercially available for the treatment of large B-cell lymphoma. This article reviews a case study to highlight a typical treatment journey for a patient with relapsed large B-cell lymphoma undergoing cellular immunotherapy, including treatment timeline and toxicities, as well as implications for advanced practice providers caring for patients with B-NHL. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF